title: Access to disease modifying treatments for rheumatoid arthritis patients.
authors.forename: D E
authors.initials: DE
authors.lastname: Furst
authors.forename: F C
authors.initials: FC
authors.lastname: Breedveld
authors.forename: G R
authors.initials: GR
authors.lastname: Burmester
authors.forename: L
authors.initials: L
authors.lastname: Crofford
authors.forename: P
authors.initials: P
authors.lastname: Emery
authors.forename: M
authors.initials: M
authors.lastname: Feldman
authors.forename: J R
authors.initials: JR
authors.lastname: Kalden
authors.forename: A
authors.initials: A
authors.lastname: Kavanaugh
authors.forename: E
authors.initials: E
authors.lastname: Keystone
authors.forename: P E
authors.initials: PE
authors.lastname: Lipsky
authors.forename: R N
authors.initials: RN
authors.lastname: Maini
authors.forename: L
authors.initials: L
authors.lastname: Moreland
authors.forename: J S
authors.initials: JS
authors.lastname: Smolen
authors.forename: L
authors.initials: L
authors.lastname: Van De Putte
authors.forename: T
authors.initials: T
authors.lastname: Vischer
authors.forename: M
authors.initials: M
authors.lastname: Weinblatt
authors.forename: M
authors.initials: M
authors.lastname: Weissman
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006801:Humans; D018579:Patient Selection; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha